FDA grants priority review to Merck’s Keytruda combo for muscle-invasive bladder cancer
Merck (NYSE:MRK), known as MSD outside the U.S. and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) involving its anti-PD-1 therapy, Keytruda.










